Zacks Small Cap Issues Positive Forecast for EVAX Earnings

Evaxion Biotech A/S (NASDAQ:EVAX) – Stock analysts at Zacks Small Cap raised their Q1 2025 earnings estimates for shares of Evaxion Biotech A/S in a research report issued to clients and investors on Thursday, February 6th. Zacks Small Cap analyst B. Sorensen now forecasts that the company will post earnings of ($0.65) per share for the quarter, up from their prior estimate of ($0.75). The consensus estimate for Evaxion Biotech A/S’s current full-year earnings is ($0.15) per share. Zacks Small Cap also issued estimates for Evaxion Biotech A/S’s Q2 2025 earnings at ($0.45) EPS, Q4 2025 earnings at ($0.12) EPS and FY2025 earnings at ($1.32) EPS.

Several other research firms have also commented on EVAX. HC Wainwright reaffirmed a “buy” rating and set a $14.00 price target on shares of Evaxion Biotech A/S in a research report on Monday, February 3rd. Lake Street Capital dropped their price target on shares of Evaxion Biotech A/S from $35.00 to $6.00 and set a “buy” rating for the company in a research report on Tuesday, February 4th.

Evaxion Biotech A/S Stock Performance

EVAX stock opened at $2.78 on Monday. The company has a market cap of $3.25 million, a P/E ratio of -1.92 and a beta of -0.28. The company has a debt-to-equity ratio of 7.99, a current ratio of 1.00 and a quick ratio of 2.80. Evaxion Biotech A/S has a 1 year low of $2.22 and a 1 year high of $23.70. The stock’s fifty day moving average price is $4.28 and its 200-day moving average price is $10.17.

Hedge Funds Weigh In On Evaxion Biotech A/S

A hedge fund recently bought a new stake in Evaxion Biotech A/S stock. Catalina Capital Group LLC bought a new position in Evaxion Biotech A/S (NASDAQ:EVAX) in the fourth quarter, according to the company in its most recent filing with the SEC. The fund bought 34,864 shares of the company’s stock, valued at approximately $29,000. Catalina Capital Group LLC owned 2.98% of Evaxion Biotech A/S as of its most recent filing with the SEC. Institutional investors and hedge funds own 11.04% of the company’s stock.

Evaxion Biotech A/S Company Profile

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.